Apatinib Prolonged Survival in Advanced Gastric Cancer

Article

The VEGFR-2 tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo, according to the results of a phase III study.

The vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo, according to the results (abstract 4003) of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3 in Chicago.

“Apatinib is the first small molecule–targeting VEGFR to show a survival benefit in advanced gastric cancer,” said Shukui Qin, MD, of PLA Cancer Center of Nanjing Bayi Hospital in Nanjing, China. “Apatinib monotherapy is a new treatment option for advanced gastric cancer patients who failed to second line of chemotherapy.”

According to Qin, more than 80% of patients who are diagnosed with advanced gastric cancer in China require chemotherapeutic treatment. Additionally, there is a strong unmet need for patients with advanced gastric cancer who fail second-line chemotherapy.

This phase III trial included patients with advanced gastric cancer who had failed prior second-line chemotherapy. The patients were randomly assigned 2:1 to 850-mg apatinib or placebo. The primary endpoint of the study was overall survival.

Results of the study revealed an almost 2-month overall survival advantage for patients assigned apatinib. The median overall survival was 6.5 months for apatinib compared with 4.7 months for placebo (P = .0027).

Progression-free survival endpoints also showed significant differences in favor of apatinib in both the full analysis set (3.6 vs 1.8 months; P < .001) and the per-protocol set (2.8 vs 1.9 months; P < .001) of patients.

The researchers also found that apatinib increased the overall response rate (2.84% vs 0%) and the disease control rate (42.05% vs 8.79%; P < .001) compared with placebo.

Patients assigned apatinib experienced significantly more adverse events compared to patients on placebo (P = .0038). However, apatinib was not found to increase severe adverse events.

Patients assigned apatinib had significantly more leukocytopenia (40.34% vs 8.79%; P < .0001), neutropenia (37.5% vs 9.89%; P < .001), and thrombocytopenia (25% vs 6.59%; P = .0002). Apatinib was also associated with significant increases in proteinuria, hypertension, and hand-foot syndrome.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content